- Home
- ITRG vs BOLD Comparison
ITRG vs BOLD Comparison
Compare ITRG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- BOLD
- Stock Information
- Founded
- ITRG 1997
- BOLD 2018
- Country
- ITRG Canada
- BOLD United States
- Employees
- ITRG N/A
- BOLD N/A
- Industry
- ITRG Precious Metals
- BOLD
- Sector
- ITRG Basic Materials
- BOLD
- Exchange
- ITRG Nasdaq
- BOLD Nasdaq
- Market Cap
- ITRG 84.2M
- BOLD 81.0M
- IPO Year
- ITRG N/A
- BOLD 2024
- Fundamental
- Price
- ITRG $1.20
- BOLD $2.95
- Analyst Decision
- ITRG Strong Buy
- BOLD Strong Buy
- Analyst Count
- ITRG 1
- BOLD 3
- Target Price
- ITRG $3.75
- BOLD $23.00
- AVG Volume (30 Days)
- ITRG 259.4K
- BOLD 57.8K
- Earning Date
- ITRG 11-12-2024
- BOLD 11-11-2024
- Dividend Yield
- ITRG N/A
- BOLD N/A
- EPS Growth
- ITRG N/A
- BOLD N/A
- EPS
- ITRG N/A
- BOLD N/A
- Revenue
- ITRG N/A
- BOLD N/A
- Revenue This Year
- ITRG N/A
- BOLD N/A
- Revenue Next Year
- ITRG $360.53
- BOLD N/A
- P/E Ratio
- ITRG N/A
- BOLD N/A
- Revenue Growth
- ITRG N/A
- BOLD N/A
- 52 Week Low
- ITRG $0.64
- BOLD $2.82
- 52 Week High
- ITRG $1.28
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- ITRG 66.49
- BOLD N/A
- Support Level
- ITRG $0.95
- BOLD N/A
- Resistance Level
- ITRG $1.28
- BOLD N/A
- Average True Range (ATR)
- ITRG 0.07
- BOLD 0.00
- MACD
- ITRG 0.01
- BOLD 0.00
- Stochastic Oscillator
- ITRG 77.27
- BOLD 0.00
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of highly prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.